Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 890-896

  Salmon, Sydney E ^a   Crowley, John J ^a   Balcerzak, Stanley P ^a   Roach, Ralph W ^a   Taylor, Sarah A ^a   Rivkin, Saul E ^a   Samlowski, Wolfram ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DOXORUBICIN; INTERFERON; PREDNISONE; QUININE; VERAPAMIL; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031934633     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.890     Document Type: Article

References (32)

1. Salmon SE, Cassady RJ: Plasma cell neoplasms, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 2344-2379
2. Salmon SE, Shadduck RK, Schilling A: Intermittent high-dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 51:179-187, 1967
3. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
4. Scheinman RI, Cogswell PC, Lofquist AK, et al: Role of transcriptional activation of I k B a in mediation of immunosuppression by glucocorticoids. Science 270:283-286, 1995
5. Auphan N, DiDonato JA, Rosette C, et al: Immunosuppression by glucocorticoids: Inhibition of NF k B activity through induction of I k B synthesis. Science 270:286-290, 1995
6. Attal M, Harousseau JL, Stoppa AM, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy. N Engl J Med 335:91-97, 1996
7. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 20:1430-1434, 1990
8. Westin J, Rödjer S, Turesson I, et al: Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study. Br J Haematol 89:561-568, 1995
9. Browman G, Bergsagel DE, Sicheri D, et al: Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13:2354-2360, 1995
10. Ludwig H, Cohen AM, Polliack A, et al: Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of others' studies. Ann Oncol 6:467-476, 1995
11. Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma. A Southwest Oncology Group study. J Clin Oncol 12:2405-2414, 1994
12. Peest D, Deicher H, Coldewey R, et al: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 89:328-337, 1995
13. Blade J, San Miguel JF, Escudero ML, et al: Maintenance treatment with interferon alpha-2b in multiple myeloma. Proceedings of the Fifth International Workshop on Multiple Myeloma, La Baule, France, 1995, pp 394-395
14. Dimopoulos MA, Weber D, Delasalle KB, et al: Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 72:2589-2592, 1993
15. Gupta V, Thompson EB, Stock-Novack D, et al: Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors: A Southwest Oncology Group study. Invest New Drugs 12:121-128, 1994
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 53:457-481, 1958
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
18. Salmon SE, Dalton WS, Grogan TM, et al: Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50, 1991
19. Grogan TM, Spier CM, Salmon SE, et al: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 81:490-495, 1993
20. Lehnert M, Dalton WS, Roe DJ, et al: Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77:348-354, 1991
21. Mickisch GH, Merlino GT, Galski H, et al: Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88:547-551, 1991
22. Taylor CW, Dalton WS, Mosley K, et al: Combination chemotherapy with cyclophosphamide, vincristine. Adriamycin, dexamethasone plus oral quinine and verapamil in patients with advanced breast cancer. Breast Can Res Treat 42:7-14, 1997
23. Miller TP, Dahlberg S, Cassady JR, et al: Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study. Proc Am Soc Clin Oncol 15:411, 1996 (abstr)
24. Sonneveld P, Schoester M, de Leeuw K: Clinical modulation of multidrug resistance in multiple myeloma: Effect of 9A cyclosporine on resistant tumor cells. J Clin Oncol 12:1584-1591, 1994
25. Dalton WS, Greipp P, Greenberg P, et al: Phase I study of the chemosensitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance. Blood 88:662a, 1996 (suppl 1, abstr)
26. Harousseau JL, Klein B: Utilisation de l'interferon alpha dans le myélome multiple. Rev Med Intern 17:488-495, 1996
27. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
28. Klein B, Zhang XG, Lu ZY, et al: Interleukin-6 in human multiple myeloma. Blood 85:863-872, 1995
29. Lichtenstein A, Tu YP, Fady C, et al: Imerleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248-255, 1995
30. Tanaka M, Tanabe O, Iwato K, et al: Sensitive inhibitory effect of interferon alpha on M protein secretion of human myeloma cells. Blood 74:1718-1722, 1989
31. Jourdan M, Shang XG, Portier M, et al: IFN-alpha induces automne production of IL-6 in myeloma cell lines. J Immunol 147:4402-4407, 1991
32. Rettig MB, Ma HJ, Vescio RA, et al: Kaposi's sarcoma-associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-1854, 1997